Experience our GMP-sites Brensbach and Neuhaus in Germany

• The international standard gives customers access to renewable alternatives
• Transparency through mass balancing creates customer confidence

Many nations are experiencing a major demographic shift in which the over-60 population will soon outweigh younger age groups. An aging population has increasing implications for the healthcare system, as older adults are at a greater risk of chronic disease and often experience challenges with non-adherence to multiple medications.

The Röchling Group is investing EUR 50 million in a new production building and production resources at its Röchling Medical site in Neuhaus am Rennweg, Germany. This is the world-leading plastics processor’s biggest investment to date in buildings and machinery. By making this investment, the Röchling Group is laying the course for the ongoing growth of its Medical division. The new building will create around 30 new jobs in Neuhaus, Thuringia.

Multiparticulates, an emerging technology with many advantages over traditional dosage forms are particularly suited for use in paediatric medicine. The Sympfiny® system is specifically tailored to administering multiparticulate drug formulations, thus opening up the way for more widesprad use of this novel dosage form in paediatrics.

Standard primary packaging solutions for solids, liquids and ophthalmologyContainers for diagnostics and analytics

Scientists at the University of Birmingham, UK have evaluated Sympfiny® as device for orally dispensing multiparticulate drugs to children aged 4-12.

Röchling Medical's innovative intelligent packaging solution against non-adherence.
Connect-e-Cap® 

• Reminds patients of the next required dose
• Records fill level, opening time etc.
• Recognizes the container via pairing function
• Reads out information regarding dosage, correct storage etc. 
• Redefines communication between doctors and patients